participants in another simultaneous clinical trial. use of other immunomodulators. coinfection with the hepatitis b virus (detectable agsup-hbv). pregnancy (or planning to become pregnant during the course of the study), or lactation period. presence of laboratory abnormalities of grade ≥ 4.

participants in another simultaneous clinical trial. use of other immunomodulators. coinfection with the hepatitis b virus (detectable agsup-hbv). pregnancy (or planning to become pregnant during the course of the study), or lactation period. presence of laboratory abnormalities of grade ≥ 4.

1. participants in another simultaneous clinical trial. 2. use of other immunomodulators. 3. coinfection with the hepatitis b virus (detectable agsup-hbv). 4. pregnancy (or planning to become pregnant during the course of the study), or lactation period. 5. presence of laboratory abnormalities of grade ≥ 4.

1. participants in another simultaneous clinical trial. 2. use of other immunomodulators. 3. coinfection with the hepatitis b virus (detectable agsup-hbv). 4. pregnancy (or planning to become pregnant during the course of the study), or lactation period. 5. presence of laboratory abnormalities of grade ≥ 4.